Analysts Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) PT at $32.73

Outlook Therapeutics, Inc. (NASDAQ:OTLK) has been assigned an average rating of “Moderate Buy” from the seven analysts that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $32.73.

Several research analysts have recently commented on the company. BTIG Research reduced their target price on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 29th. Chardan Capital reissued a “neutral” rating on shares of Outlook Therapeutics in a report on Monday, December 2nd. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Outlook Therapeutics in a report on Friday, November 29th.

Outlook Therapeutics Price Performance

Shares of OTLK opened at $2.30 on Monday. The company has a market capitalization of $57.28 million, a P/E ratio of -0.21 and a beta of 0.53. Outlook Therapeutics has a one year low of $0.87 and a one year high of $12.85. The business’s 50 day simple moving average is $2.87 and its 200-day simple moving average is $5.41.

Outlook Therapeutics (NASDAQ:OTLK) last announced its earnings results on Friday, December 27th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.06. On average, sell-side analysts anticipate that Outlook Therapeutics will post -3.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC bought a new position in Outlook Therapeutics in the 2nd quarter worth approximately $75,000. Christensen King & Associates Investment Services Inc. bought a new stake in shares of Outlook Therapeutics during the 3rd quarter valued at $55,000. Barclays PLC raised its position in shares of Outlook Therapeutics by 677.4% during the 3rd quarter. Barclays PLC now owns 20,943 shares of the company’s stock valued at $111,000 after acquiring an additional 18,249 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Outlook Therapeutics by 55.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 51,459 shares of the company’s stock valued at $275,000 after acquiring an additional 18,287 shares during the last quarter. Finally, State Street Corp raised its position in shares of Outlook Therapeutics by 10.0% during the 3rd quarter. State Street Corp now owns 232,542 shares of the company’s stock valued at $1,242,000 after acquiring an additional 21,201 shares during the last quarter. Institutional investors own 11.20% of the company’s stock.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.